Table 1.
Enrichment analysis by pathway.
| Pathway maps | *Total | P-value | FDR |
|---|---|---|---|
| Cell adhesion_Ephrin signaling | 45 | 1.384E-07 | 2.076E-05 |
| Neurophysiological process_GABA-A receptor life cycle | 27 | 4.311E-06 | 7.674E-04 |
| Neurophysiological process_GABA-B receptor signaling at postsynaptic sides of synapses | 42 | 2.628E-05 | 2.339E-03 |
| Neurophysiological process_Dopamine D2 receptor signaling in CNS | 47 | 4.125E-05 | 2.448E-03 |
| Signal transduction_PKA signaling | 51 | 5.711E-05 | 2.541 E-03 |
| Neurophysiological process_Receptor-mediated axon growth repulsion | 45 | 1.010E-04 | 7.573E-03 |
| Neurophysiological process_Dopamine D2 receptor transactivation of PDGFR in CNS | 26 | 1.530E-04 | 1.683E-02 |
| Neurophysiological process_HTR1 A receptor signaling in neuronal cells | 26 | 1.530E-04 | 1.683E-02 |
| G-protein signaling_G-Protein alpha-i signaling cascades | 27 | 1.856E-04 | 6.608E-03 |
| Neurophysiological process_Mu-type opioid receptor-mediated analgesia | 30 | 2.554E-04 | 7.578E-03 |
*Total refers to the total number of genes involved in a pathway. False discovery rate (FDR) and P-value refer to pathways involved in the experimental conditions. A P-value <0.01 is considered significant.